Francesc Artigas, Esther Schenker, Pau Celada, Michael Spedding, Laia Lladó-Pelfort, Noemi Jurado, Mercedes Núñez, Noemi Santana, Eva Troyano-Rodriguez, Maurizio S Riga, Hanna van den Munkhof, Anna Castañé, Hamdy Shaban, Thérèse M Jay, Anushree Tripathi, Bill P Godsil, Claude Sebban, Jean Mariani, Philippe Faure, Samir Takkilah, Zoe A Hughes, Chester J Siok, Mihaily Hajos, Karsten Wicke, Natalia Gass, Wolfgang Weber-Fahr, Alexander Sartorius, Robert Becker, Michael Didriksen, Jesper F Bastlund, Mark Tricklebank, Céline Risterucci, Andreas Meyer-Lindenberg, Adam J Schwarz
Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.
November 4, 2016: Nature Reviews. Drug Discovery